Mumbai, Feb. 5 -- Revenue from operations grew by 12.32% to Rs 1,614.28 crore in the quarter ended 31 December 2024.

Profit before tax stood at Rs 487.59 crore in the third quarter of FY25, up 15.49% from Rs 422.16 crore posted in the same period a year ago.

On nine-month basis, the pharma company's net profit grew 14.57% to Rs 1,047.40 crore on 8.94% rise in revenue from operations to Rs 4,804.56 crore in 9M FY24 over 9M FY23.

Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

Published by HT Digital Content Services with permission from Capital Market....